// App-Quantinova.ai

786 : Effects of combination treatment with cabozantinib and bortezomib in the 5TGM1 murine multiple myeloma model

Researchers

Presenter

  • Mari I. Suominen

Principal Investigators

  • Katja M. Fagerlund

  • Esa Alhoniemi

  • Jukka P. Rissanen

  • Jussi M. Halleen

  • Dana T. Aftab

Medical Centers

  • Pharmatest Services Ltd, Turku, Finland.

  • Avoltus Oy, Turku, Finland

Locations

  • Finland

Companies

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Multiple Myeloma

  • Bone metastases

  • Prostate cancer

  • Hypercalcaemia

  • Solid malignancies

Biomarkers

  • AXL receptor tyrosine kinase

  • Procollagen I amino-terminal propeptide

  • Ret Proto-Oncogene

  • Kinase Insert Domain Receptor

  • Stromal interaction molecule 1

  • Vascular endothelial growth factor A

Drug/Treatment

  • Cabozantinib

  • Bortezomib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved